Form 8-K

TorreyPines Therapeutics (TPTX)

Annual Reports

Quarterly Reports

8-K

Other

Documents found in this filing:

Annual Reports

Quarterly Reports

8-K

Other

Documents found in this filing:

TorreyPines Therapeutics (TPTX)

	SUMMARY

	BULLS

	BEARS

	TOPICS

	DATA CENTRAL

	STOCK CHART

	SEC FILINGS

	BALANCE

	INCOME

	CASH FLOW

8-K (Jul 7, 2016)8-K (May 27, 2016)8-K (May 13, 2016)8-K (May 5, 2016)8-K (Mar 15, 2016)8-K (Feb 25, 2016)8-K (Feb 9, 2016)8-K (Dec 10, 2015)8-K (Nov 5, 2015)8-K (Oct 5, 2015)8-K (Sep 14, 2015)8-K (Sep 9, 2015)8-K (Sep 8, 2015)8-K (Aug 21, 2015)8-K (Aug 6, 2015)8-K (Jul 17, 2015)8-K (May 20, 2015)8-K (May 18, 2015)8-K (May 7, 2015)8-K (Apr 3, 2015)8-K (Feb 26, 2015)8-K (Feb 13, 2015)8-K (Jan 7, 2015)8-K (Dec 18, 2014)8-K (Nov 6, 2014)8-K (Oct 24, 2014)8-K (Aug 21, 2014)8-K (Aug 7, 2014)8-K (Aug 5, 2014)8-K (Aug 4, 2014)8-K (Jul 29, 2014)8-K (Jul 8, 2014)8-K (Jul 3, 2014)8-K (May 8, 2014)8-K (Mar 13, 2014)8-K (Feb 26, 2014)8-K (Feb 24, 2014)8-K (Jan 22, 2014)8-K (Jan 14, 2014)8-K (Dec 12, 2013)8-K (Nov 7, 2013)8-K (Sep 12, 2013)8-K (Aug 8, 2013)8-K (Jul 25, 2013)8-K (Jul 23, 2013)8-K (Jul 5, 2013)8-K (Jul 2, 2013)8-K (Jun 25, 2013)8-K (May 24, 2013)8-K (May 9, 2013)8-K (May 1, 2013)8-K (Apr 9, 2013)8-K (Mar 15, 2013)8-K (Jan 9, 2013)8-K (Dec 26, 2012)8-K (Dec 7, 2012)8-K (Nov 15, 2012)8-K (Nov 6, 2012)8-K (Nov 2, 2012)8-K (Oct 1, 2012)8-K (Sep 12, 2012)8-K (Aug 20, 2012)8-K (Jul 31, 2012)8-K (Jul 12, 2012)8-K (Jun 25, 2012)8-K (Jun 19, 2012)8-K (Jun 14, 2012)8-K (May 25, 2012)8-K (May 14, 2012)8-K (May 1, 2012)8-K (Apr 26, 2012)8-K (Apr 19, 2012)8-K (Apr 12, 2012)8-K (Mar 30, 2012)8-K (Dec 21, 2011)8-K (Oct 26, 2011)8-K (Sep 28, 2011)8-K (Sep 19, 2011)8-K (Sep 8, 2011)8-K (Jul 26, 2011)8-K (Jul 25, 2011)8-K (Jun 28, 2011)8-K (Apr 13, 2011)8-K (Apr 7, 2011)8-K (Mar 22, 2011)8-K (Feb 15, 2011)8-K (Nov 26, 2010)8-K (Nov 17, 2010)8-K (Nov 12, 2010)8-K (Aug 24, 2010)8-K (Aug 13, 2010)8-K (Aug 10, 2010)8-K (Jun 30, 2010)8-K (Jun 17, 2010)8-K (Apr 22, 2010)8-K (Apr 8, 2010)8-K (Feb 5, 2010)8-K (Dec 24, 2009)8-K (Dec 23, 2009)8-K (Dec 18, 2009)8-K (Dec 15, 2009)8-K (Nov 17, 2009)8-K (Nov 3, 2009)8-K (Oct 9, 2009)8-K (Oct 7, 2009)8-K (Oct 5, 2009)8-K (Jul 31, 2009)8-K (Jul 28, 2009)8-K (Jul 22, 2009)8-K (Jun 17, 2009)8-K (May 29, 2009)8-K (May 1, 2009)8-K (Apr 24, 2009)8-K (Apr 2, 2009)8-K (Mar 31, 2009)8-K (Mar 27, 2009)8-K (Feb 9, 2009)8-K (Dec 2, 2008)8-K (Dec 1, 2008)8-K (Nov 26, 2008)8-K (Nov 12, 2008)8-K (Nov 10, 2008)8-K (Oct 7, 2008)8-K (Oct 2, 2008)8-K (Sep 25, 2008)8-K (Aug 26, 2008)8-K (Aug 8, 2008)8-K (Jun 23, 2008)8-K (Jun 17, 2008)8-K (May 13, 2008)8-K (Mar 26, 2008)8-K (Mar 25, 2008)8-K (Feb 14, 2008)8-K (Nov 14, 2007)8-K (Oct 22, 2007)8-K (Sep 25, 2007)8-K (Aug 14, 2007)8-K (May 14, 2007)8-K (Mar 29, 2007)8-K (Feb 7, 2007)8-K (Jan 17, 2007)8-K (Dec 20, 2006)8-K (Dec 13, 2006)8-K (Oct 19, 2006)8-K (Oct 10, 2006)8-K (Oct 4, 2006)8-K (Sep 28, 2006)8-K (Sep 6, 2006)8-K (Aug 30, 2006)8-K (Aug 29, 2006)8-K (Aug 7, 2006)8-K (Aug 4, 2006)8-K (Jun 20, 2006)8-K (Jun 12, 2006)8-K (Jun 8, 2006)8-K (Mar 13, 2006)8-K (Jan 6, 2006)8-K (Dec 22, 2005)8-K (Dec 6, 2005)8-K (Sep 20, 2005)8-K (Sep 16, 2005)8-K (Jul 27, 2005)8-K (Jun 30, 2005)8-K (Jun 22, 2005)8-K (May 16, 2005)8-K (May 5, 2005)8-K (Apr 7, 2005)8-K (Mar 14, 2005)8-K (Mar 9, 2005)8-K (Feb 7, 2005)8-K (Oct 15, 2004)8-K (Jun 10, 2004)8-K (Jun 4, 2004)8-K (May 5, 2004)8-K (Mar 30, 2004)8-K (Jan 20, 2004)8-K (Jan 12, 2004)8-K (Sep 16, 2003)8-K (Jun 18, 2003)8-K (Apr 7, 2003)8-K (Mar 4, 2003)8-K (Dec 20, 2002)8-K (Mar 6, 2002)8-K (Dec 13, 2001)8-K (Nov 6, 2000)8-K (Jun 1, 1999)

HORIZON PHARMACEUTICAL LLC 8-K 2014

Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 1, 2014

RAPTOR PHARMACEUTICAL CORP.

(Exact name of registrant as specified in its charter)

Delaware

000-25571

86-0883978

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification Number)

7 Hamilton Landing, Suite 100

Novato, California 94949

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (415) 408-6200

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01

Entry into a Material Definitive Agreement.

As previously disclosed, on July 1, 2014, Raptor Pharmaceutical Corp. (the “Company”) entered into an amended and restated loan agreement (the “Amended and Restated Loan Agreement”) with HealthCare Royalty Partners II, L.P., as lender (the “Lender”), which revises the terms of the loan agreement, dated as of December 20, 2012, between the Company and the Lender.

A copy of the Amended and Restated Loan Agreement is filed herewith as Exhibit 10.1. Certain information has been omitted from the Amended and Restated Loan Agreement pursuant to a request for confidential treatment filed with the Securities and Exchange Commission.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits.


Exhibit No.		Exhibit Description

10.1^*		Amended and Restated Loan Agreement, dated as of July 1, 2014, by and among Healthcare Royalty Partners II, L.P., Raptor Pharmaceutical Corp. and the Guarantors party thereto.

*	Certain information omitted pursuant to a request for confidential treatment filed with the SEC.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Exhibit Index


Exhibit No.		Exhibit Description

10.1^*		Amended and Restated Loan Agreement, dated as of July 1, 2014, by and among Healthcare Royalty Partners II, L.P., Raptor Pharmaceutical Corp. and the Guarantors party thereto.

*	Certain information omitted pursuant to a request for confidential treatment filed with the SEC.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.

Mobile | Advertise | Licensing & Partnerships | Blogger Tools | Jobs

Date: August 21, 2014

RAPTOR PHARMACEUTICAL CORP.

/s/ Georgia Erbez

Georgia Erbez

Chief Financial Officer, Secretary and Treasurer